RM-END / Endocrine and peptide-hormone analogs
Histrelin
Also known as: Supprelin LA · Histrelin acetate · Vantas
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Histrelin is a synthetic nonapeptide GnRH agonist. The labeled comparator is a hydrogel implant that controls release over time, not a generic peptide vial.
Evidence position
The regulated implant and human evidence support Grade A for the named finished product.
What the record does not establish
The implant record does not authenticate loose histrelin or transfer its release, dose, sterility and device controls.
Sources
- 01Histrelin compound recordPubChem
- Shows
- Registry identity, structure, formula and synonyms for histrelin
- Does not show
- Does not establish the acetate implant, release system or lot quality
- 02Supprelin LA prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label, nonapeptide identity and controlled-release implant presentation
- Does not show
- Does not qualify loose histrelin, another salt, route or release system
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Histrelin
- CID
- 25077993
- Formula
- C66H86N18O12
- Mass
- 1323.5
PUBMED / FOUND RECORDS
- Histrelin. / 2012PMID 31643395
- Histrelin: in advanced prostate cancer.Drugs / 2010 Mar 26PMID 20329807 / DOI 10.2165/11204800-000000000-00000
- Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study.PloS one / 2025PMID 40644420 / DOI 10.1371/journal.pone.0327842
- Gonadotropin Releasing Hormone (GnRH) Analogues. / 2012PMID 31643199
- Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.Drugs / 1993 AprPMID 7684676 / DOI 10.2165/00003495-199345040-00008
CLINICALTRIALS.GOV / FOUND RECORDS
- Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate CancerCOMPLETED / PHASE3 / Endo USA Inc., a Keenova Therapeutics CompanyNCT01697384 / DIRECT intervention MATCH: Histrelin
- The Relation of GnRH Treatment to QTc Interval in Transgender FemalesTERMINATED / NO PHASE / University of California, San FranciscoNCT03078829 / DIRECT intervention MATCH: Histrelin
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRECRUITING / PHASE2 / Mayo ClinicNCT06378866 / DIRECT intervention MATCH: Histrelin
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCOMPLETED / PHASE2 / University of Colorado, DenverNCT02278185 / DIRECT intervention MATCH: Histrelin
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialACTIVE_NOT_RECRUITING / PHASE3 / NRG OncologyNCT05050084 / DIRECT intervention MATCH: Histrelin